{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T04:55:34Z","timestamp":1781844934807,"version":"3.54.5"},"reference-count":28,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012190","name":"Ministry of Science and Higher Education of the Russian Federation","doi-asserted-by":"crossref","award":["075-15-2025-013"],"award-info":[{"award-number":["075-15-2025-013"]}],"id":[{"id":"10.13039\/501100012190","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Background\/Objectives: Latent tuberculosis infection (LTBI) is a persistent immune response to Mycobacterium tuberculosis antigens in the absence of clinically active tuberculosis. It is now established that progression from LTBI to active tuberculosis is directly associated with immune dysregulation, which frequently occurs in immune-mediated diseases requiring treatment with immunosuppressive agents. The aim of this study was to identify LTBI in patients with rheumatological diseases receiving immunosuppressive therapy using contemporary immunodiagnostic methods. Materials and Methods: A retrospective, prospective, group-control study was conducted, analyzing the results of immunodiagnostics in patients with rheumatological diseases on immunosuppressive therapy and without established contact with tuberculosis patients (n = 44; main group). The control group consisted of healthy individuals (n = 51) with no history of tuberculosis contact, clinical or radiological manifestations of the disease, or signs of chronic pathology exacerbation. Both groups were predominantly female (72.7% in the main group and 62.8% in the control group). The mean age in the patient group was 49.1 years (95% CI [44.77; 53.43]). Rheumatoid arthritis was diagnosed in 29.6% (13) of patients (95% CI [16.06; 43.03]). Articular syndrome was observed in at least 72.7% (32) of patients (95% CI [59.57; 85.89]). In 54.6% (24) of cases (95% CI [39.83; 69.26]), patients received biologic immunosuppressive therapy as basic treatment. In 15.9% (7) of cases (95% CI [5.10; 26.72]), patients received conventional synthetic disease-modifying antirheumatic drugs (DMARDs). Of these, 71.43% (5) (95% CI [35.24; 92.44]) underwent comprehensive examination to exclude active tuberculosis prior to biologic therapy initiation. For immunodiagnostics, all subjects underwent an interferon-gamma release assay (IGRA) and\/or testing with a recombinant tuberculosis antigen (ATR) sample, with dynamic assessment of test results. All patients with positive immunodiagnostic results underwent multidetector computed tomography of the chest organs. The level of LTBI in the comparison groups was defined as the percentage of positive immunological test results at a significance level of p &lt; 0.05. Statistical data processing was performed using Microsoft Excel 2019. Results: In the main group, positive immunodiagnostic results were recorded in 20.5% (9) of cases (95% CI [8.54; 32.37]), which is significantly higher than in the control group of healthy individuals (5.8% (3), 95% CI [1.41; 16.54]). This reflects statistically significant differences in immunological test results between groups receiving and not receiving immunosuppressive therapy (\u03c72 = 4.545, p = 0.034). Dynamic evaluation of the ATR sample revealed positive results in 21.7% (5) of cases (95% CI [4.88; 38.60]), with four out of five patients demonstrating positive conversion. In the third assessment, positivity was observed in 33.33% (5) of cases (95% CI [9.48; 57.19]), which was higher than in the first (\u03c72 = 1.025, p = 0.312) and second assessments (\u03c72 = 0.629, p = 0.428), although these differences were not statistically significant. Notably, in two out of five patients, the ATR test result changed from negative to positive. Conclusions: In patients with rheumatological diseases receiving immunosuppressive therapy, LTBI was detected in 20.5%, which is significantly higher than in healthy individuals (5.8%, p = 0.034). Furthermore, there was an increase in the proportion of positive tests over time (up to 21.7% and 33.3% on immunotherapy), suggesting an increasing risk of progression to active tuberculosis infection.<\/jats:p>","DOI":"10.3390\/diagnostics16121883","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T08:22:56Z","timestamp":1781684576000},"page":"1883","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Detection of Latent Tuberculosis Infection in Patients with Rheumatological Diseases Who Receive Immunosuppressive Therapy"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9023-6986","authenticated-orcid":false,"given":"Anna","family":"Starshinova","sequence":"first","affiliation":[{"name":"Almazov National Research Medical Center, 197341 St. Petersburg, Russia"},{"name":"Department of Mathematics and Computer Science, Saint Petersburg State University, 199034 St. Petersburg, Russia"},{"name":"Medical Department, Bashkir State Medical University of the Ministry of Health of the Russian Federation, 450008 Ufa, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adilia","family":"Sabirova","sequence":"additional","affiliation":[{"name":"Department of Mathematics and Computer Science, Saint Petersburg State University, 199034 St. Petersburg, Russia"},{"name":"Medical Department, Bashkir State Medical University of the Ministry of Health of the Russian Federation, 450008 Ufa, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey","family":"Maslyanskiy","sequence":"additional","affiliation":[{"name":"Almazov National Research Medical Center, 197341 St. Petersburg, Russia"},{"name":"Institute of Medicine, Department of Pathology, St. Petersburg State University, 199034 St. Petersburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Grigorieva","sequence":"additional","affiliation":[{"name":"Almazov National Research Medical Center, 197341 St. Petersburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul","family":"Sharipov","sequence":"additional","affiliation":[{"name":"Medical Department, Bashkir State Medical University of the Ministry of Health of the Russian Federation, 450008 Ufa, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravil","family":"Tukfatullin","sequence":"additional","affiliation":[{"name":"Medical Department, Bashkir State Medical University of the Ministry of Health of the Russian Federation, 450008 Ufa, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandr","family":"Panteleev","sequence":"additional","affiliation":[{"name":"Medical Department, St. Petersburg State Medical University Named after Academician I.P. Pavlov, 197022 St. Petersburg, Russia"},{"name":"St. Petersburg Research Institute of Phthisiopulmonology, 190961 St. Petersburg, Russia"},{"name":"St. Petersburg State Budgetary Healthcare Institution \u201cCity Tuberculosis Dispensary\u201d, 196142 St. Petersburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michail","family":"Nazarenko","sequence":"additional","affiliation":[{"name":"Medical Department, Bashkir State Medical University of the Ministry of Health of the Russian Federation, 450008 Ufa, Russia"},{"name":"St. Petersburg State Budgetary Healthcare Institution \u201cCity Tuberculosis Dispensary\u201d, 196142 St. Petersburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1878-4467","authenticated-orcid":false,"given":"Dmitry","family":"Kudlay","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Institute of Pharmacy, I.M. Sechenov First Moscow State Medical University, 119991 Moscow, Russia"},{"name":"FSBI SSC Institute of Immunology FMBA of Russia, 115522 Moscow, Russia"},{"name":"Faculty of Bioengineering and Bioinformatics, Lomonosov Moscow State University, 119991 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2018). Latent Tuberculosis Infection: Updated and Consolidated Guidelines for Programmatic Management, WHO."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/oxfordjournals.aje.a121593","article-title":"The prognosis of a positive tuberculin reaction in childhood and adolescence","volume":"99","author":"Comstock","year":"1974","journal-title":"Am. J. Epidemiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e002726","DOI":"10.1136\/rmdopen-2022-002726","article-title":"Systematic literature review informing the 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases","volume":"8","author":"Fragoulis","year":"2022","journal-title":"RMD Open"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"103758","DOI":"10.1016\/j.autrev.2025.103758","article-title":"Assessment and management for latent tuberculosis before advanced therapies for immune-mediated inflammatory diseases: A comprehensive review","volume":"24","author":"Jha","year":"2025","journal-title":"Autoimmun. Rev."},{"key":"ref_5","unstructured":"World Health Organization (2014). Guidelines on the Management of Latent Tuberculosis Infection, WHO."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e14996","DOI":"10.1111\/1756-185X.14996","article-title":"Screening, prophylaxis, and challenges: Tumor necrosis factor inhibitors and latent tuberculosis infection nexus in rheumatology","volume":"27","author":"Su","year":"2024","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/ard-2022-223357","article-title":"Safety of synthetic and biological DMARDs: A systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"82","author":"Sepriano","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"115","DOI":"10.18565\/pharmateca.2024.4.115-120","article-title":"Diagnostic capabilities of recombinant tuberculosis allergen in patients with rheumatic diseases","volume":"31","author":"Mordyk","year":"2024","journal-title":"Pharmateca"},{"key":"ref_9","first-page":"83","article-title":"Risk of latent tuberculosis in the cohort of patients with rheumatoid arthritis in Slovakia","volume":"70","year":"2021","journal-title":"Epidemiol. Mikrobiol. Imunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"102","DOI":"10.14412\/1996-7012-2019-3-102-108","article-title":"Comorbid infections in patients with rheumatoid arthritis: Status praesens","volume":"13","author":"Belov","year":"2019","journal-title":"Sovrem. Revmatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/1744666X.2019.1705785","article-title":"Infection risk in patients undergoing treatment for inflammatory arthritis: Non-biologics versus biologics","volume":"16","author":"Chiu","year":"2020","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"105632","DOI":"10.1016\/j.msard.2024.105632","article-title":"Latent tuberculosis prevalence, diagnosis and treatment in multiple sclerosis as a strategy for reducing infection reactivation during immunosuppressant therapy","volume":"86","author":"Reis","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2282182","DOI":"10.1080\/07853890.2023.2282182","article-title":"Latent tuberculosis infection in myasthenia gravis patients on immunosuppressive therapy: High incidence yet moderate reactivation rate","volume":"55","author":"Chen","year":"2023","journal-title":"Ann. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/ajd.14340","article-title":"Evaluation of serial QuantiFERON-TB Gold In-Tube test results in patients with psoriasis receiving anti-IL-17 therapy","volume":"65","author":"Hapa","year":"2024","journal-title":"Australas. J. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1007\/s10067-024-07279-7","article-title":"Systemic vasculitis with latent tuberculosis infection and associated factors: A multicenter study","volume":"44","author":"Zhong","year":"2025","journal-title":"Clin. Rheumatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e0084823","DOI":"10.1128\/spectrum.00848-23","article-title":"Latent tuberculosis infection and associated factors in patients with systemic lupus erythematosus","volume":"11","author":"Zhang","year":"2023","journal-title":"Microbiol. Spectr."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Frolova, X.S., and Borisov, S.E. (2020). Monitoring of latent tuberculosis infection in patients with inflamm atory bowel diseases under anti-tumor necrosis factor therapy. Tuberc. Soc. Signif. Dis., 20\u201325. (In Russian).","DOI":"10.1183\/13993003.congress-2020.482"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.jiph.2024.04.016","article-title":"The risk of tuberculosis infection in Saudi patients receiving adalimumab, etanercept, and tocilizumab therapy","volume":"17","author":"Boqaeid","year":"2024","journal-title":"J. Infect. Public Health"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1093\/ced\/llae549","article-title":"Safety of interleukin-17A inhibitors in patients with psoriasis with or without latent tuberculosis: A dual-centre retrospective study","volume":"50","author":"Hu","year":"2025","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S1473-3099(14)71085-0","article-title":"Latent tuberculosis infection in rural China: Baseline results of a population-based multicentre prospective cohort study","volume":"15","author":"Gao","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.3904\/kjim.2016.222","article-title":"Agreement between latent tuberculosis screening tests among patients with rheumatic diseases: Systematic review","volume":"33","author":"Pyo","year":"2018","journal-title":"Korean J. Intern. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/apt.16952","article-title":"Review article: Latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression-risks, screening, diagnosis and management","volume":"56","author":"Fehily","year":"2022","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"60","DOI":"10.18093\/0869-0189-2011-0-1-60-64","article-title":"A Skin test with recombinant allergen of mycobacterium tuberculosis (diaskintest\u00ae) to detect tuberculosis in hiv patients","volume":"1","author":"Slogotskaya","year":"2011","journal-title":"Pulmonologiya"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"335","DOI":"10.4103\/ijmy.ijmy_131_20","article-title":"Recombinant tuberculosis allergen (diaskintest\u00ae) in tuberculosis diagnostic in russia (meta-analysis)","volume":"9","author":"Starshinova","year":"2020","journal-title":"Int. J. Mycobacteriol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"58","DOI":"10.21292\/2075-1230-2019-97-5-58-65","article-title":"Immunodiagnostics of tuberculosis: 10-year experience of using immunological tests in Russia","volume":"97","author":"Starshinova","year":"2019","journal-title":"Tuberc. Lung Dis."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Vasilyeva, I.A., Aksenova, V.A., Kazakov, A.V., Kiseleva, Y.Y., Maryandyshev, A.O., Dolzhenko, E.N., Abramchenko, A.V., Klevno, N.I., Glebov, K.A., and Panova, A.E. (2023). Evaluation of the specificity of an intradermal test with recombinant tuberculosis allergen in Bacillus Calmette-Gu\u00e9rin-vaccinated healthy volunteers. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1042461"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"59","DOI":"10.21292\/2075-1230-2019-97-9-59-67","article-title":"Screening for tuberculosis infection in children and adolescents in Russia\u2014Past, present, future","volume":"97","author":"Aksenova","year":"2019","journal-title":"Tuberc. Lung Dis."},{"key":"ref_28","first-page":"16","article-title":"New screening and diagnostic options of various traits of tb infection among children and adolescents in Russia","volume":"10","author":"Aksenova","year":"2011","journal-title":"Curr. Pediatr."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/12\/1883\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T04:46:02Z","timestamp":1781844362000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/12\/1883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":28,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["diagnostics16121883"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics16121883","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]}}}